Evreux, France and Montreal, Canada, October 17, 2017 – CiToxLAB, a leading Contract Research Organization (CRO), announces the purchase of a new facility in Laval (Montreal, Canada) to meet the growing demand for bioanalysis and biomarkers services in support of preclinical and clinical programs, offering shorter lead times for development programs.

The newly acquired ultra-modern facility is a turn-key, purpose-built laboratory dedicated to small and large molecule bioanalysis by LC-MS/MS and ligand binding assays, flow cytometry, biomarkers, biodistribution by qPCR and immunology, including anti-drug antibody, neutralizing antibody, immunophenotyping and ELISPOT. This expansion is an integral part of the strategic plan for CiToxLAB’s growth in global laboratory services.The new building will bring an additional 20,000 sq ft (2,000m²) of state-of–the-art laboratory and office space to serve the company’s North American client base.

“This expansion is the result of successful partnerships with our clients. It reinforces CiToxLAB’s commitment to enhancing the way we serve our customers. The relocation of some of our laboratory operations to this new building will free up areas in the main building, allowing us to increase our animal room capacity, resulting in shorter lead times for our clients. The availability of this building, next door to our site in Laval, was an unexpected but excellent opportunity. I am very satisfied that our fast decision-making led CiToxLAB to acquiring this building in this ever-growing suburb of Montreal, where competition for this type of real estate is very high,” said Jean-François Le Bigot, Chairman and CEO of CiToxLAB Group.

Andrew Graham, Site Manager at CiToxLAB North America, stated “We currently partner with eight of the top ten global pharmaceutical companies and about 200 biotech companies; we work with these customers at a very early stage on the development of their drug candidates, performing pharmacology and safety studies. These studies include bioanalysis and biomarkers investigations for which, in many cases, we have developed and validated the methods, often specific to their compounds. In that context, more and more customers consider it appropriate to continue working with us during the initial clinical trials in order to save time and money, and to avoid the added risk related to the transfer of methods between labs. The new building we have just purchased will allow us to better meet the increasing needs of our clients for a one-stop-shop CRO in laboratory sciences investigations.”

About CiToxLAB Group
With six facilities located in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), Denmark (Copenhagen) and Hungary (Veszprem),  CiToxLAB Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. CiToxLAB carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. CiToxLAB and Atlanbio also offer both preclinical and clinical bioanalysis and biomarkers services. With AccelLAB in the group, CiToxLAB now offers efficacy and safety studies in medical devices (cardiology, ENT, orthopedics, and regenerative medicine). A partnership with Stemina (Madison, USA) allows the group to offer screening services using human embryonic stem cell models. Today, CiToxLAB has more than 1,100 employees working at six sites representing 700,000 sq ft (65,000m²) of state-of-the-art facilities. The company has a world-class, top-level management team in scientific, financial and business activities.
www.citoxlab.com